Le Lézard
Classified in: Health, Covid-19 virus
Subject: OFR

Foresee Pharmaceuticals Announces Completion of US$47 Million Financing


TAIPEI, Dec. 24, 2020 /PRNewswire/ -- Foresee pharmaceuticals (TPEx: 6576.TWO) ("Foresee") announces that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88 per share. The aggregate gross proceeds to Foresee from the offering were approximately US$47 million (NT$1.32 billion).

The proceeds of the Public Offering will be used for general corporate purposes, which include supporting Foresee's existing drug research and development programs ? such as FP-025, for which a Phase II/III clinical trial IND application was recently submitted to the FDA for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients.

In addition to the progress of FP-025, Foresee's Camcevitm 42 mg, a ready-to-use 6-month depot formulation of leuprolide mesylate, is currently under review process by the FDA and EMA, which will soon be followed by Camcevitm 3-month depot; FP-045, an orally bioavailable ALDH2 activator, which previously obtained permission from the FDA to proceed with the clinical study, is planned to enter into a Phase 1/2 dose-finding study in adolescent and pediatric patients with Fanconi anemia.

Previously this year, Foresee has completed a round of private placement financing, raising approximately US$3 million (NT$90 million) by the issuance of 1,200,000 shares of common stock at a price of NT$75.

About Foresee Pharmaceuticals Co., Ltd.

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange. Foresee's R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, secondly its transformative preclinical and clinical first-in-class NCE programs targeting disease areas with high unmet needs.

Foresee's product portfolio includes late stage and early stage programs such as FP-001, 6-month and 3-month, stable, ready-to-use versions of leuprolide mesylate for injection, for which regulatory approval reviews are currently underway in US and EU for the 6-month product and regulatory submissions for 3-month product are in preparation; FP-025, a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in a Phase 2 proof-of-concept study, and target to initiate Phase 2 study for COVID-19 virus induced acute respiratory distress syndrome (ARDS); FP-045, a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia, and FP-004, a novel, subcutaneously injectable product in development for the treatment of opioid use disorder and pain. www.foreseepharma.com


These press releases may also interest you

at 18:30
Technavio has been monitoring the laboratory glassware and plasticware market and it is poised to grow by USD 843.1 mn during 2020-2024, progressing at a CAGR of almost 4% during the forecast period. The report offers an up-to-date analysis regarding...

at 18:30
SandRidge Energy, Inc. (the "Company" or "SandRidge") today announced financial and operational results for the quarter and fiscal year ended December 31, 2020....

at 18:25
SelectQuote, Inc. ("SelectQuote" or the "Company"), a pioneer in providing consumers with unbiased price comparisons from some of the most trusted insurance carriers, today announced the pricing of a proposed secondary public offering of 10,600,000...

at 18:25
Churchill Capital Corp II, ("Churchill II") , a special purpose acquisition company which has entered into a definitive agreement to merge with Software Luxembourg Holding S.A. ("Skillsoft"), a global leader in digital learning and talent management...

at 18:21
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Lizhi Inc.  pursuant and/or traceable to Lizhi's January 17, 2020 initial public offering (the "IPO" or the "Offering") of the important March 22, 2021...

at 18:20
Parex Resources Inc. ("Parex" or the "Company") is a company headquartered in Calgary, Alberta that focuses on sustainable, profitable, conventional oil and gas production. The Company is pleased to announce its financial and operating results for...



News published on 24 december 2020 at 05:00 and distributed by: